Kornimate/medical-research-clean huggingface dataset:
agaricus bisporus and influenza vaccination response

Conditions: Immune Response

Summary: there are numerous in vitro and animal studies that suggested that mushrooms beneficially influence the immune system. we have recently shown that a wild isolate of the edible agaricus bisporus mushroom had a clear effect on parameters reflecting a better function of the immune system, both in vitro and in vivo in animals. the question now is whether this efficacy can also be translated to humans. in humans, measuring the antibody response is the golden standard to evaluate immune function. if agaricus bisporus powder indeed has beneficial effects on the immune system, people with overweight or obesity and higher age might benefit from consuming agaricus bisporus powder prior to receiving the influenza vaccination.


Eligibility criteria:
inclusion criteria: * aged 60 years or older during influenza season 2023/2024 (in line with rivm guidelines) * bmi between 20 and 35 kg/m2 * willing to abstain from mushrooms other than the capsules containing a mushroom powder as provided by us during the study period. * willing to keep the intake of fish oil, zinc, selenium and (vitamin) supplements constant * willing to abstain from products / supplements enriched with vitamin d * willing to abstain from products / supplements enriched with plant sterols or stanols * willing to abstain from products / supplements enriched with (β)glucans or fungi. * willing to abstain from products / supplements that are mentioned to "boost your immune system" * willing to abstain from (products enriched in) pre/pro-biotics * willing to abstain from products/supplements enriched with ergothioneine exclusion criteria: * already received influenza vaccination in 2023 * allergy to mushrooms * known allergic reaction to an active component or other components of the vaccine (e.g. chicken eggs) * having donated blood within one month prior to the start of the study, or planning to donate blood during the study * excessive alcohol use (\>20 consumptions per week) * regular use of soft and/or hard drugs * using medication for diseases known to affect inflammation/immunity (e.g. inhaled corticosteroids and prednisone)

Keywords: agaricus bisporus immune system influenza vaccination mushroom
yoga and mbsr for tth

Conditions: Tension-Type Headache

Summary: primary study objectives 1. evaluate the short-term effect of yoga intervention in addition to routine care on headache frequency in patients with frequent or chronic tension-type headache compared to routine care alone (waiting group). 2. to evaluate the short-term effect of yoga intervention in addition to routine care on headache frequency in patients with frequent episodic or chronic tension-type headache compared with stress management through mindfulness-based stress reduction (mbsr) in addition to routine care. secondary study objectives evaluation of the medium-term effect of the intervention on headache frequency as well as the short- and medium-term effect on the secondary target parameters in comparison to the waiting group and mbsr. further evaluation of the safety and acceptability of the intervention.


Eligibility criteria:
inclusion criteria: * episodic or chronic tension-type headache according to ichd-3 definition exclusion criteria: * medication induced headache according to ichd-3 definition * cluster-headache according to ichd-3 definition * serious chronic systemic or acute physical or mental illness * dementia * pregnancy * actual in a yoga or mbsr class

Keywords: tension-type headache yoga mindfulness-based stress reduction
advanced radiotherapy (art) in prostate cancer (prost-art)

Conditions: Prostate Cancer

Summary: this is a retrospective monoinstitutional study which analyses the results of advanced radiotherapy (igrt, imrt, sbrt, and pet-guided) performed for radical, adjuvant, or salvage purposes in patients with low, intermediate, high, and very high-risk prostate cancer, or with biochemical, lymph node, or oligometastatic recurrence treated between 2004 and 2024. approved by ethics committee of irccs san raffaele hospital approval number: 187/int/2021, 03/02/2022 amendment approved by ethics committee 1, lombardy region approval number cet em. 194-2024, 22/05/2024

this is a single-center, retrospective study (prost-art) that has as its primary objective the evaluation of the efficacy of radiotherapy treatments performed in patients with early-stage, advanced, metastatic prostate disease, with biochemical relapses after surgery, with local relapses after radiotherapy, or oligometastatic/oligoprogressive disease. the aim of the study is to measure the biochemical relapse-free survival (brfs), local and regional relapse (lr, regional relapse, rr), distant metastases-free survival (dms), clinical relapse (dfs), disease-free survival (pcss), and overall survival (os) from both disease diagnosis and the end of radiotherapy until the last useful follow-up, or until the patient's death. in addition, the acute and late toxicity of treatments will be assessed from the start of treatment until the last follow-up/death of the patient and the period without other oncological treatments, from the end of treatment until the start of another oncological treatment/last follow-up. at least 200 patients treated in the last 5 years, some receiving stereotactic radiotherapy to the prostate, or prostate and seminal vesicles, and the others pelvic lymph node and prostate irradiation, who are still alive and contactable, and agree to participate, will be included in a survey on quality of life (qol). these patients, after signing an informed consent for the collection of new information, will receive an eortc qlq-pr25 quality of life questionnaire, in order to quantify the impact of toxicity. in addition, the radiomic characteristics of the computed tomography/ pet-ct performed for treatment planning along with evaluation of the results will be extracted to identify related predictive factors. the qol study is configured as retrospective as the questionnaire will only be an expression, from the patient's point of view, of the toxicity of the previous treatment.

Eligibility criteria:
inclusion criteria: * prostate cancer patients, \> 18 years old, treated with igrt, imrt, sbrt exclusion criteria: * other tumors * \> 95 years old

Keywords: prostate cancer radical radiotherapy adjuvant radiotherapy salvage radiotherapy stereotactic body radiotherapy (sbrt) simultaneous integrated boost oligometastatic disease bone metastases lymph-node metastases choline pet/ct psma pet/ct pet guidance
epileptic seizures in intensive care units

Conditions: Epileptic Seizure

Summary: this retrospective observational cohort study is to assess and analyze clinical, electroencephalographic, laboratory, comorbidity, and treatment characteristics of intensive care unit (icu)-patients with epileptic seizures and to subsequently compare their characteristics with icu-patients with status epilepticus (se).

the aim of this retrospective observational cohort study is to get further insight into adult patients with epileptic seizures in icus in an academic tertiary medical care center regarding frequency, clinical and electroencephalogram (eeg) characteristics, treatment, course and outcome. this data could help understanding the epidemiology (including risk factors, influence of eeg), and to guide management and improve outcomes of affected patients.

Eligibility criteria:
inclusion criteria: * admitted to the icu at the university hospital basel * suffered from one or more epileptic seizures (detected clinically and/or by eeg) during their icu-stay exclusion criteria: * patients with epileptic seizures transforming into status epilepticus (se)

Keywords: status epilepticus electroencephalogram intensive care unit
pharmacokinetic and tolerability study of nfc-1 in subjects aged 6-17 years with adhd

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: this is a open-label, single ascending dose, pharmacokinetic, and tolerability study of nfc-1 in children and adolescents (ages 6-17 years) with adhd.


Eligibility criteria:
inclusion criteria: 1. subject and parent/legally authorized representative (lar) are able to speak english fluently and have provided written informed consent, and assent (as applicable) for this study. 2. subject is 6 to 17 years inclusive at the time of consent/assent. 3. subject is male, female of non-childbearing potential or non-pregnant, non-lactating female of childbearing potential who agrees to comply with any applicable contraceptive requirements 2 weeks prior to administration of ip and throughout the study. 4. subject meets diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) criteria for a primary diagnosis of adhd based on a m.i.n.i. international neuropsychiatric interview. 5. subject is considered "healthy". healthy status is defined by absence of evidence of any active or chronic disease other than their adhd following a detailed medical and surgical history, a complete physical examination. 6. subject has the ability to swallow a capsule of investigational product whole. exclusion criteria: 1. subject has a history of any hematological, hepatic, respiratory, cardiovascular, renal, neurological, or psychiatric disease, gall bladder removal, or current or recurrent disease other than their adhd. 2. subject has a current or relevant history of physical or psychiatric illness, or any medical disorder that may require treatment. 3. subject has a current, controlled or uncontrolled, comorbid psychiatric diagnosis with significant symptoms. 4. subject is considered a suicide risk in the opinion of the investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. 5. subject has used an investigational product, been enrolled in a clinical study including vaccines, or had any changes in eating habits, within 30 days prior to the first dose of investigational product. 6. subject has a positive screen for alcohol or drugs of abuse, or a positive hepatitis b surface antigen (hbsag), hepatitis c virus (hcv), or hiv antibody screen. 7. subject previously was an adolescent (12-17) who was either a screen failure, or enrolled or participated in this study or another nfc1 clinical study. 8. subject is currently taking any medication that might confound the results of safety assessments conducted in the study. 9. subject has a concurrent chronic or acute illness, disability, or other condition that might confound the results of safety assessments conducted in the study. 10. subject is unwilling to discontinue current adhd medication to participate in the study. 11. subject has a clinical laboratory abnormality that indicates clinically significant hematologic, hepatobiliary, or renal disease.
effect of acetazolamide on lung water content by ultrasound in lowlanders older than 40 years at altitude

Conditions: Altitude Hypoxia

Summary: randomized, placebo controlled trial evaluating the effect of acetazolamide on lung water content by ultrasound in lowlanders older than 40 years travelling from 760 m to 3'100 m.

this is a randomized, placebo-controlled, double-blind parallel trial evaluating the effect of preventive acetazolamide intake on lung water content by ultrasound in lowlanders older than 40 years travelling to altitude. participants living in the bishkek area, kyrgyzstan (760m), will be transferred by car within 4h to the tuja ashu high altitude clinic (3'100 m), and stay there for 2 days. acetazolamide 375mg/day (or placebo), will be administered before departure at 760 m and during the stay at altitude. outcomes will be assessed during the stay at 3'100 m. an interim analysis will be carried out when 200 participants will have completed the study and/or after the first year. the peto's method will be used and the trial will be stopped when pre-specified futility boundaries were crossed.

Eligibility criteria:
inclusion criteria: * healthy men and women, age 40-75 yrs, without any disease and need of medication. * born, raised and currently living at low altitude (\<800m). * written informed consent. * kyrgyz ethnicity exclusion criteria: * any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure. * any condition that may interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day or \>20 pack-years with active smoking during the last 10 years), regular use of alcohol. * allergy to acetazolamide and other sulfonamides.

Keywords: healthy participants older than 40 years lung water prevention acetazolamide
study for the artificial pancreas project : determination of a tuning strategy of metabolic profiles

Conditions: Type 1 Diabetes

Summary: the artificial pancreas project developed by supelec and the university hospital of rennes is focused on the evaluation of an original control algorithm that computes appropriate subcutaneous insulin infusion in response to continuous glucose measurements the results during a 24-hour closed-loop period will be compared with those of the open-loop. the implementation of this algorithm named error dynamics shaping (eds) requires as a preliminary a phase of identification of the parameters of the model (insulin pharmacokinetics and effect on glucose metabolism) followed by a phase of optimization i.e. a personalized adjustment of the damping parameters of eds. the present study aims to formalize this procedure of identification/optimization of the parameters of the model and controller eds. they will be determined in type -1 diabetic patients using insulin therapy and under conditions free from disturbances such as those generated by the glucidic meals, i.e. during a period of glucidic fast. three variables will determine this procedure: blood glucose, insulin concentration and insulin doses.


Eligibility criteria:
inclusion criteria: * type 1 diabetic patients (age : 18-70) * diabetes duration higher than three years * insulin pump with humalog® * hospitalized for a 24-hour glucidic fast test * written informed consent exclusion criteria: * pregnancy or nursing * acute infectious disease * corticoid treatment * creatinine clearance \<40 ml/mn * patients using apidra® or novorapid® * people major being the object of a legal protection (safeguard of justice, supervision, trusteeship)
combined aerobic exercise and cognitive training in seniors with genetic susceptibility for alzheimer's disease

Conditions: Alzheimer Disease

Summary: the study aims to investigate the effect of a long-term combined aerobic exercise and cognitive training program on cognitive function, daily function, psychosocial status, and neural plasticity in seniors with genetic susceptibility for alzheimer's disease.

alzheimer's disease (ad) is the most common type of dementia and the leading cause of disability in people older than 65 years worldwide. however, there is no effective disease-modifying therapy currently. therefore, improvement of cognitive function in people at risk and, potentially, prevention of cognitive decline has been gaining attraction. our previous research reported a model of a combination single nucleotide polymorphism (snp) (rs3777215, rs234434, rs71352238, and rs4420638) can predict ad onset with high performance, which is useful to identify people at risk for ad and thus allows for timely treatment and prevention. both aerobic exercise and cognitive training have been demonstrated beneficial effects on cognition in subjects with ad and healthy populations. moreover, the synergistic effects of the combination have been proven recently. however, the effect of combined aerobic exercise and cognitive training on seniors with genetic susceptibility for ad remains to be elucidated. herein, this study aims to 1. assess the effects of long-term combined aerobic exercise and cognitive training on cognitive function, daily function, psychosocial status, and neural plasticity in seniors with single nucleotide polymorphism of rs3777215, rs234434, rs71352238, and rs4420638. 2. confirm the predictive value of the snp model for ad in a longitudinal setting.

Eligibility criteria:
inclusion criteria: * mandarin-speaking subjects. * not clinically demented. * meeting the cutoff values of mmse and cdr. * with positive variation of rs3777215, rs234434, rs71352238, and rs4420638. exclusion criteria: * had major neurologic diagnosis (e.g., parkinson's disease, stroke, encephalitis, and epilepsy) or other condition that might impair cognition or confound assessments. * had a history of psychotic episodes or had major depression (hamilton depression rating scale score \> 24 points). * had severe systemic diseases, such as tumors, cardiovascular or orthopedic disorder that can affect the ability to perform the proposed intervention tasks.

Keywords: alzheimer's disease cognitive training prevention aerobic exercise genetic susceptibility neural plasticity
an observational study of mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients on dialysis with renal anemia

Conditions: Anemia

Summary: this observational study will evaluate the use in clinical practice and efficacy of mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients on dialysis receiving mircera for the treatment of chronic renal anemia. eligible patients will be followed for 24 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, 18 to 65 years of age, inclusive * patients with chronic kidney disease on dialysis * esa naïve with hb \< 10 g/dl, or on treatment with esas other than mircera and hb within the target range of 10-12 g/dl * adequate irons status as judged by the treating physician exclusion criteria: * hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication * clinically significant concomitant disease or disorder as defined by protocol * clinical suspicion of pure red cell aplasia (prca) * planned elective surgery during the study period , except for cataract surgery or vascular access surgery * transfusion of red blood cells in the previous 2 months * pregnant women * contraindications for mircera according to local prescribing information or as judged by the investigator
study on treatment decision-making and prognostic follow-up for untreated cerebral cavernous malformations

Conditions: Hemangioma, Cavernous, Central Nervous System

Summary: the goal of this observational study is to evaluate and predict the risk associated with cerebral cavernous malformations (ccms) using advanced artificial intelligence and radiomics analysis technology. the study focuses on individuals who have been diagnosed with cerebral cavernous malformations (ccms). main questions to answer: how can ai-based radiomics features predict the risk of complications (such as bleeding or epilepsy) in individuals with ccms? what are the most reliable imaging and clinical markers for assessing the prognosis of ccms? participants will be required to undergo regular medical imaging to gather traditional and radiomics imaging features. participants will provide clinical data, including past medical history and results of any laboratory tests. participants will be part of a three-year follow-up observation to monitor the progression or stability of ccms. contribution of biological samples for advanced testing might also be requested. this study aims to create an ai-based decision-making tool that will guide clinicians in the management of ccm, with the potential to significantly improve patient outcomes through personalized medical approaches.


Eligibility criteria:
inclusion criteria: 1. diagnosis of ccm based on brain mri (t1, t2, swi, and t2-fluid-attenuated inversion recovery). 2. patients who have not received invasive treatment (surgery, radiotherapy, or multimodal therapy) in the past. 3. patients undergoing surgery, or their legal guardians, agree to collect lesion tissue samples for related studies and sign a consent form for the collection of biological samples. 4. patients under conservative observation, or their legal guardians, agree to collect imaging data for related research and sign a consent form for the use of imaging data. 5. willingness to participate in long-term follow-up. exclusion criteria: 1. patients with acute intracranial symptomatic hemorrhage requiring emergency surgery. 2. patients with other intracranial diseases, such as aneurysms, tumors, or other vascular malformations, excluding developmental venous anomalies (dva). 3. patients with severe underlying diseases affecting their functional status and short-term life expectancy. 4. patients with severe psychiatric or psychological disorders. 5. incomplete clinical or imaging data.
osteoclast impairment in chronic periodontitis by regenerative materials.

Conditions: Periodontal Disease; Periodontal Bone Loss; Osteoclastic Bone Loss

Summary: the present study is an effort to investigate the hypothesis that platelet rich fibrin/biphasic calcium phosphate may play a role in inhibiting osteoclasts differentiation and in bone loss.

study design fifty-five individuals from a suburban population were recruited. out of them, 5 individuals refused to participate in the study. finally, 50 participants were selected and divided into two groups, control group \[healthy individuals\]: 25 males/females, aged 25 to 35 years and test group \[chronic periodontitis patients\]: 25 males/females aged 30 to 45 years. demographic variables and periodontal parameters were measured in both the groups.the investigators explored the effect of platelet rich fibrin (prf)/biphasic calcium phosphate (bcp) on differentiation and survival of osteoclasts obtained from peripheral blood of chronic periodontitis patients.

Eligibility criteria:
inclusion criteria: (control group) * subjects with age group between 30 to 45 years. * non-smokers. * no previous history of periodontal treatment. inclusion criteria: (test group) * subjects with age group between 30 to 45 years. * presence of atleast 20 teeth * more than 30% of the sites with clinical attachment loss. * non-smokers. * no previous history of periodontal treatment. exclusion criteria: ( both the groups) * individuals with systemic disease * subjects under antibiotics or anti-inflammatory drugs within the previous 3 months. * pregnant and lactating women. * allergic to antibiotics.

Keywords: biomaterials apoptosis bone regeneration